← Back to Search

Anticoagulant

Apixaban for Deep Vein Thrombosis (VTE Trial)

Phase 2
Waitlist Available
Led By Oya Tugal, MD
Research Sponsored by New York Medical College
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Treatment with apixaban has to begin within 72 hours of the diagnosis of VTE.
Patients who have received heparin at the beginning of their diagnosis and are willing to switch to apixaban, are allowed to do so within 72 hours of their treatment. Patients who are switched to apixaban are not allowed to receive any other systemic anticoagulant therapy.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 8-15
Awards & highlights

VTE Trial Summary

This trial tests whether apixaban is more effective than placebo at preventing a secondary thromboembolism in patients who have already developed a venous thrombosis.

Eligible Conditions
  • Deep Vein Thrombosis

VTE Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

VTE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 8-15
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 8-15 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
venous thromboembolism (VTE) formation
Secondary outcome measures
Doppler ultrasound vein imaging

Side effects data

From 2018 Phase 4 trial • 557 Patients • NCT01884337
7%
Incision site pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
TOTAL KNEE REPLACEMENT (TKR)
TOTAL HIP REPLACEMENT (THR)

VTE Trial Design

1Treatment groups
Experimental Treatment
Group I: AbixabanExperimental Treatment1 Intervention
Apixaban 10 mg twice daily p.o. for seven days followed by 5 mg twice daily p.o. for children and adolescents weighting ≥40 kg who have been diagnosed with a thrombosis.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Apixaban
FDA approved

Find a Location

Who is running the clinical trial?

New York Medical CollegeLead Sponsor
69 Previous Clinical Trials
5,986 Total Patients Enrolled
Oya Tugal, MDPrincipal InvestigatorNew York Medical College

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~3 spots leftby Mar 2025